Neuroprotective factors affect the progression of Alzheimer's disease

被引:1
|
作者
Liu, Yan [1 ]
Tian, Jinzhou [1 ]
机构
[1] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Neurol, Beijing, Peoples R China
关键词
Alzheimer's disease; Biomarkers; Molecular; Target; Protective role; MILD COGNITIVE IMPAIRMENT; AMYLOID-BETA LEVELS; HISTONE ACETYLATION; GENETIC-VARIATION; BIOMARKERS; HIPPOCAMPUS; ASSOCIATION; EXPRESSION; ONSET; IDENTIFICATION;
D O I
10.1016/j.bbrc.2023.09.042
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease(AD) is a neurodegenerative disease that occurs mostly in the elderly and is characterized by chronic progressive cognitive dysfunction, which seriously threatens the health and life-quality of patients. Alterations at the molecular level, which causes pathological changes of AD brain, have impacted the progression of AD. In this review, we illustrate the recent evidence of the alteration of neuroprotective proteins in AD, such as changes in their contents and variants. Furthermore, we elucidate the single nucleotide polymorphism (SNP) and gene changes. Finally, we highlight the epigenetic changes in AD, which helps to display the characteristics of the disease and provides guidance regarding research hot spots in the field against AD.
引用
收藏
页码:276 / 282
页数:7
相关论文
共 50 条
  • [1] Cholinesterase inhibitors affect disease progression in Alzheimer's disease
    Marini, S.
    Bessi, V.
    Padiglioni, S.
    Nacmias, B.
    Bagnoli, S.
    Sorbi, S.
    Bracco, L.
    JOURNAL OF NEUROLOGY, 2013, 260 : S165 - S165
  • [2] Cardiovascular Disease Risk Factors and Progression of Alzheimer's Disease
    van Kan, Gabor Abellan
    Rolland, Yves
    Nourhashemi, Fati
    Coley, Nicola
    Andrieu, Sandrine
    Vellas, Bruno
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2009, 27 (03) : 240 - 246
  • [3] Vascular risk factors and progression in Alzheimer's disease
    Sakurai, Hirofumi
    Hanyu, Haruo
    Sato, Tomohiko
    Kanetaka, Hidekazu
    Shimizu, Soichiro
    Hirao, Kentaro
    Kikukawa, Masayuki
    Iwamoto, Toshihiko
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2011, 11 (02) : 211 - 214
  • [4] Hypoxia-inducible factors as neuroprotective agent in Alzheimer's disease
    Ashok, Ben Sundra
    Ajith, Thekkuttuparambil Ananthanarayanan
    Sivanesan, Senthilkumar
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2017, 44 (03) : 327 - 334
  • [5] Comorbid major depression may affect progression of Alzheimer's disease
    Naccari, C
    CNS SPECTRUMS, 2006, 11 (03) : 169 - 170
  • [6] Neuroprotective therapies for Alzheimer's disease
    Huber, A
    Stuchbury, G
    Bürkle, A
    Burnell, J
    Münch, G
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (06) : 705 - 717
  • [7] Neuroprotective treatment of Alzheimer's disease
    Mielke, R
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1996, 121 (48) : 1515 - 1515
  • [8] Neuroprotective Strategies in Alzheimer's Disease
    Longo F.M.
    Massa S.M.
    NeuroRX, 2004, 1 (1): : 117 - 127
  • [9] Neuroprotective strategies in Alzheimer's disease
    Behl, C
    MOLECULAR AND CELLULAR BIOLOGY OF NEUROPROTECTION IN THE CNS, 2002, 513 : 475 - 496
  • [10] Analysis of factors affecting rate of progression of Alzheimer's disease
    Barker, WW
    Duara, R
    Loewenstein, D
    Cantillon, M
    Hurwitz, D
    Mullan, M
    StGeorgeHyslop, P
    NEUROLOGY, 1996, 46 (02) : 6014 - 6014